Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
AstraZeneca(US:AZN) Businesswire·2024-02-19 15:00Daiichi Sankyo和AstraZeneca的合作 - Datopotamab deruxtecan (Dato-DXd)的Biologics License Application (BLA)已被美国接受，用于治疗晚期或转移性非鳞状非小细胞肺癌患者[1] - Datopotamab deruxtecan是一种TROP2定向DXd抗体药物结合物（ADC），由Daiichi Sankyo和AstraZeneca共同开发[2] - BLA基于TROPION-Lung01关键试验的结果，该试验在欧洲医学肿瘤学协会（ESMO23）2023年大会的总统研讨会上展示了显著的进展[4]